6号染色体缺失破坏急性淋巴细胞白血病中的FOXO-PRDM1轴
该研究以B细胞急性淋巴细胞白血病(B-ALL)中6q大片段缺失为模型,整合功能cDNA克隆追踪、患者基因组与转录组数据分析,鉴定FOXO3和PRDM1为候选抑癌基因;过表达二者可协同促进前B细胞阶段细胞周期退出,CRISPR-Cas9筛选显示FOXO3为抑癌基因而FOXO1为B-ALL生长所必需;泛FOXO激动剂Selinexor在低剂量(ID50 < 50 nM)下诱导糖酵解抑制因子TXNIP并抑制B-ALL生长。
要点
- FOXO3和PRDM1被鉴定为B-ALL中6q缺失的候选抑癌基因。
- FOXO3与PRDM1协同促进前B细胞阶段细胞周期退出。
- CRISPR-Cas9筛选显示FOXO3为抑癌基因,FOXO1为B-ALL生长必需。
核心结论
- 6q缺失通过破坏FOXO-PRDM1轴参与B-ALL发病,FOXO3和PRDM1为候选抑癌基因。
- FOXO3具有白血病保护作用,与抑制糖酵解相关;FOXO1则对B-ALL生长必需。
- 泛FOXO激动剂Selinexor在低剂量(ID50 < 50 nM)下可诱导TXNIP并抑制B-ALL生长。
研究设计与样本
- 研究以B-ALL和6q大片段缺失[del(6q)]为模型,整合功能cDNA克隆追踪 assays 与患者基因组及转录组数据分析。
- 采用CRISPR-Cas9筛选鉴定FOXO3为抑癌基因、FOXO1为B-ALL生长必需基因。
- 通过过表达FOXO3或PRDM1分析细胞周期与转录组变化,并整合CRISPR数据与FOXO1/FOXO3诱导或抑制的基因集进行分析。
主要发现
- 过表达FOXO3或PRDM1的细胞周期与转录组分析表明二者协同促进前B细胞阶段细胞周期退出。
- FOXO1在B-ALL中无异常,但与FOXO3一样,其过表达在体外抑制TCF3::PBX1和ETV6::RUNX1 B-ALL生长。
- FOXO1和FOXO3均诱导PRDM1及其他参与晚期前B细胞发育的基因,仅FOXO1诱导关键转录因子IRF4和趋化因子CXCR4。
- CRISPR-Cas9筛选鉴定FOXO3为抑癌基因,而FOXO1为B-ALL生长所必需。
- 泛FOXO激动剂Selinexor在低剂量(ID50 < 50 nM)下诱导糖酵解抑制因子TXNIP并抑制B-ALL生长。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A common problem in the study of human malignancy is the elucidation of cancer driver mechanisms associated with recurrent deletion of regions containing multiple genes. Taking B-cell acute lymphoblastic leukaemia (B-ALL) and large deletions of 6q [del(6q)] as a model, we integrated analysis of functional cDNA clone tracking assays with patient genomic and transcriptomic data, to identify the transcription factors FOXO3 and PRDM1 as candidate tumour suppressor genes (TSG). Analysis of cell cycle and transcriptomic changes following overexpression of FOXO3 or PRDM1 indicated that they co-operate to promote cell cycle exit at the pre-B cell stage. FOXO1 abnormalities are absent in B-ALL, but like FOXO3, FOXO1 expression suppressed growth of TCF3::PBX1 and ETV6::RUNX1 B-ALL in-vitro. While both FOXOs induced PRDM1 and other genes contributing to late pre-B cell development, FOXO1 alone induced the key transcription factor, IRF4, and chemokine, CXCR4. CRISPR-Cas9 screening identified FOXO3 as a TSG, while FOXO1 emerged as essential for B-ALL growth. We relate this FOXO3-specific leukaemia-protective role to suppression of glycolysis based on integrated analysis of CRISPR-data and gene sets induced or suppressed by FOXO1 and FOXO3. Pan-FOXO agonist Selinexor induced the glycolysis inhibitor TXNIP and suppressed B-ALL growth at low dose (ID50 < 50 nM).
引用
- Sinclair PB, Cranston RE, Raninga P, et al. Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia. 2023. PMID: 36670235. doi:10.1038/s41375-023-01816-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。